We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fastnet Equity | FAST | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.975 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.975 | 2.975 |
| Top Posts |
|---|
Posted at 16/4/2016 12:12 by barnes4 Amyt investors got 4% of the new company at a 30% discountSo imagine it is they that are forward selling |
Posted at 15/4/2016 16:30 by jacksonpollack I hope this gets more exciting next week, than the past few weeks which have been a bore. It has loads of money, it has some fantastic investments and it has a world class board. But at the moment it has no interest from investors. |
Posted at 06/4/2016 13:54 by buffythebuffoon Fair comment pap as far as UK small oil companies are concerned, which is what you're thinking of. I said production assets though, not companies, and there are a large number in the Permian basin and elsewhere.Still, my main point was that we put the money into another of Friels interests after, apparently, scanning the globe for opportunities. Again, as I've said elsewhere, falling in love with a company/director is best avoided. We're both investors here, so we want the same thing. Buffy |
Posted at 05/4/2016 15:19 by papillon BWD. The following is from: It applies to the shares of America companies, but is equally applicable in this case. "Stock[edit] Par value stock has no relation to market value and, as a concept, is somewhat archaic. The par value of a share of stock is the value stated in the corporate charter below which shares of that class cannot be sold upon initial offering; the issuing company promises not to issue further shares below par value, so investors can be confident that no one else will receive a more favorable issue price. Thus, par value is the nominal value of a security which is determined by the issuing company to be its minimum price. This was far more important in unregulated equity markets than in the regulated markets that exist today, where a stock issuance prices must usually be published. The par value of stock remains unchanged in a bonus stock issue but it changes in a stock split. Par value also has accounting purposes. It allows the company to put a de minimis value for the stock on the company's financial statement" |
Posted at 05/4/2016 13:11 by sea7 BWD, nope 0.038 is the par value of the shares. It has no bearing on the share price and is also the lowest value that the company can issue shares.The new shares look like having a par value of 1p. No bearing on the 24p placing price and expected start price on the 19th april. 1p will be the lowest price they can issue shares at, without reducing it further through capital reorganisation. Historically it was the figure shown on share certificates and was there to ensure that investors could be assured that no one else was getting a more favourable price at the initial offering. Not really used much these days, apart from some accounting use. In todays more regulated markets prices are published, so par value is less important. |
Posted at 02/4/2016 16:38 by ali47fish i am completely at a loss here- i thought this placing is restricted to institutional investors- if this is still correct when would be the most advantageous time to buy for retail investoes- is a simple question but i suspect people here might not be able or willing to guess? any comments welcome |
Posted at 31/3/2016 13:57 by papillon "The Mcap will therefore be 5 times bigger and we'll have 1/8 the number of shares."I can see maths isn't your strong point buffy. Before the acquisition 345.37m. After the acquisition and share consolidation we will have 208.34m shares. That doesn't equate to 1/8th the number of shares! The Mkt Cap @ 24p per share (after the acquisition and share consolidation) will be circa £50m and with circa 3/5ths the number of shares in issue. Hopefully a £50m Mkt Cap and a more respectable share price will attract some institutional investors. |
Posted at 21/2/2016 18:51 by jacksonpollack Fastnet equity shareholders who were in fastnet oil and gas before 16/12/15 will be beneficiaries of any sale of oil and gas assets held in the trust fund. Davy stockbrokers and cathal friel being two massive shareholders together with several other institutional investors. Davy stockbrokers are the ones helping to find finance for fastnet investment. If oil and gas assets were to be sold cathal friel, Davy and all other institutional investors could use the money they gain from oil and gas assets being sold to acquire finance for pharma deal and or any future deals. As institutional investors hold the majority of shares in fastnet equity and the trust company and were there before cut off date, it could be a sizeable amount to reinvest. It would show the confidence the institutions have in fastnets new venture/s. As well as being a director of fastnet equity cathal is a director of the oil and gas trust company and a director of raglan as well as others, so finding finance shouldn't be a problem. |
Posted at 08/1/2016 22:57 by papillon Since the FAST share price dropped below the 200 day EMA back in the early summer of 2013 it's been downhill ever since for the FAST share price However now, for the first time in almost 3 years, the FAST share price is back above the 200 day EMA. Has the tide finally turned for the FAST sp? The recent news flow suggests yes!!free stock charts from uk.advfn.com A close above the August high of 2.93p on good volume would indicate that a double bottom chart pattern had formed and a POSSIBLE short term target of 4p beckons. Certainly the appointment of the big hitter, Harry Stratford, to the FAST BoD has caught the imagination of many investors. Many cash shells with a big hitter on the BoD have traded/do trade at a hefty premium to cash value as investors see big potential ahead. free stock charts from uk.advfn.com |
Posted at 22/12/2015 20:31 by jacksonpollack Sea7. FFS.CHEMICAL ATTRACTION-HARRY STRATFORD ON HOW TO BUILD A SUCCESSFUL DRUG COMPANY Posted on Nov 20, 2014 by Dr. Julie Nixon | Tags: Intellectual Property, Pharmaceuticals, BioQuarter, entrepreneur | 0 Comments By Julie Nixon On Tuesday the 18th November we were very privileged to have Harry Stratford OBE present for the latest Edinburgh BioQuarter networking event. Harry was a founder of Shire plc, one of the United Kingdom's largest pharmaceutical businesses, and later he was a founder of ProStrakan based in Galashiels. Harry told us how both companies based their business models on the “Speciality Pharma Model” (developing and commercialising drugs for the treatment of unmet therapeutic needs), in-licensing and developing products but also out-licensing those products they couldn’t market. Shire was founded in 1986 with a view to producing products for metabolic bone disease. Shire's initial products were calcium supplements (Calcichew-D3) for patients seeking to treat or prevent osteoporosis. Interestingly for an off patent drug, Calcichew in 2007 ranked 12th among branded drug products in the UK. This is an excellent example of how important a brand can be for a product’s success, and how investors can recoup their investment without the need for a patent. Harry remained chief executive at Shire until 1994, leaving to start ProStrakan in 1995. Products were in-licensed for development for application in metabolic bone disease and dermatology. Harry was Chief Executive at ProStrakan until he became Executive Chairman in 2004; he was then Non-Executive Chairman from 2006 until he retired at the end of 2007. Japan's Kyowa Hakko Kirin acquired ProStrakan in 2011 for £292m. Harry then spoke about the key lessons he learned as an entrepreneur. Sustainability for a business is key to success, and for that a company needs a great team and to know the potential of those products it in-licenses. Investor confidence is also key; the success of a company’s first product can go some way to securing investor confidence. Later Harry was asked what value he brought to the companies; was it because he identified the right drugs with the potential to be developed, or did he just market the drugs better. Harry answered that it depended on the particular drug product, but he definitely played a factor in identifying the potential value for off patent calcium products that big pharma had not been interested in. Harry also credited Shire and Prostrakan’s ability to get products to market quicker than big pharma, being smaller companies they had quicker response times in decision making. Carmel Reilly of Neurocentrx Pharma asked Harry if he would do things the same if he was starting again today. The answer was a resounding yes! The Speciality Pharma Model works! Harry also stressed the importance of cash flow from out-licensing, and how selling on those products that are out-licensed and not core IP to the company can be a useful way of fund raising. Harry now has no connection with either Shire or Prostrakan, although interestingly Prostrakan is run by his son. Harry however is last to know of any company developments! Many thanks to Edinburgh BioQuarter and Howard Marriage for bringing us this super event. Julie blog comments powered by Disqus - See more at: hxxp://mbmcommercial |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
